GlassScriptPhysician profile
Elisabeth S Roter
NPI 1548366370
$89,015.26
in general payments reported to CMS, 2019-2025
41 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $23K · 2021: $9,954 · 2022: $7,466 · 2023: $12K · 2024: $3,780 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,338 · Consulting Fee: $1,620 · Education: $198 · Travel and Lodging: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,824.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,337.50 |
| Consulting Fee | $1,620.00 |
| Education | $198.00 |
| Travel and Lodging | $135.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33,121.96 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $19,639.31 | 2019-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $17,437.99 | 2019-2025 | |
| Janssen Biotech, INC. | $3,488.39 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $3,155.67 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $3,084.64 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,939.01 | 2019-2025 | |
| Genentech USA, INC. | $1,155.79 | 2019-2025 | Actemra, Rituxan, Gazyva |
| E.R. Squibb & Sons, L.L.C. | $1,035.75 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $901.92 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $711.27 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $414.16 | 2019 | |
| Radius Health, INC. | $364.44 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.37 | 2020-2025 | Cyltezo, Ofev, Jardiance |
| Mallinckrodt Hospital Products INC. | $342.21 | 2020-2024 | Acthar |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisabeth Roter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.